ClearPoint Neuro (CLPT) Current Deferred Revenue (2011 - 2026)

ClearPoint Neuro has disclosed Current Deferred Revenue across 16 years of filings, most recently posting $1.8 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $1.8 million, down 8.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 8.15% YoY), and the FY2025 annual result was $2.2 million, up 6.08% from the prior year.
• Current Deferred Revenue came in at $1.8 million for Q1 2026 at ClearPoint Neuro, down from $2.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $3.2 million in Q4 2023 to a low of $541000.0 in Q1 2022.
• The 5-year median for Current Deferred Revenue is $1.3 million (2023), against an average of $1.5 million.
• Across the five-year window, Current Deferred Revenue jumped 136.78% in 2023 and plunged 32.75% in 2024, its largest moves.
• ClearPoint Neuro's Current Deferred Revenue stood at $1.5 million in 2022, then surged by 116.47% to $3.2 million in 2023, then slumped by 32.75% to $2.1 million in 2024, then grew by 6.08% to $2.2 million in 2025, then slipped by 19.38% to $1.8 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.8 million (Q1 2026), $2.2 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.